Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
264.8 USD | +0.78% | -1.37% | -8.47% |
Apr. 17 | UBS Adjusts Amgen's Price Target to $284 From $314, Maintains Neutral Rating | MT |
Apr. 16 | Amgen Plans for Phase 3 Trial of Tezepelumab for Lung Disease | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.47% | 141B | |
+27.86% | 672B | |
+24.52% | 550B | |
-6.78% | 351B | |
+14.92% | 317B | |
+6.45% | 292B | |
+2.77% | 211B | |
0.00% | 203B | |
-11.53% | 144B | |
-3.73% | 113B |
- Stock Market
- Equities
- AMGN Stock
- News Amgen Inc.
- Amgen : to Acquire Five Prime Therapeutics for $1.9 Billion to Strengthen Oncology Portfolio, Support Global Expansion